New combo before surgery shows promise for tough breast cancer
NCT ID NCT05525767
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study is testing whether adding bevacizumab to standard chemotherapy before surgery can help shrink tumors in people with early or locally advanced HER2-negative breast cancer. About 75 participants will receive the combination treatment, and researchers will measure how many achieve a complete response (no cancer left in the breast tissue). The goal is to improve outcomes for this type of breast cancer, which does not respond to HER2-targeted therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.